Baird Financial Group Inc. lowered its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 33.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,448 shares of the company's stock after selling 6,141 shares during the period. Baird Financial Group Inc.'s holdings in BioNTech were worth $1,134,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently bought and sold shares of the company. Banque Cantonale Vaudoise purchased a new stake in BioNTech in the first quarter valued at approximately $36,000. Costello Asset Management INC purchased a new stake in BioNTech in the 1st quarter worth approximately $91,000. Goodman Advisory Group LLC purchased a new stake in BioNTech in the 1st quarter worth approximately $105,000. Whittier Trust Co. boosted its position in BioNTech by 3,846.2% in the 1st quarter. Whittier Trust Co. now owns 2,052 shares of the company's stock worth $187,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Probity Advisors Inc. boosted its position in BioNTech by 8.5% in the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock worth $224,000 after purchasing an additional 154 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.
BioNTech Trading Down 7.3%
Shares of BNTX traded down $7.57 during midday trading on Friday, reaching $96.74. The company had a trading volume of 5,152,296 shares, compared to its average volume of 874,805. BioNTech SE Sponsored ADR has a 1-year low of $81.20 and a 1-year high of $131.49. The stock has a market cap of $23.26 billion, a PE ratio of -60.46 and a beta of 1.39. The firm has a 50 day simple moving average of $108.79 and a 200-day simple moving average of $103.91. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.
BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). The business had revenue of $306.46 million for the quarter, compared to analysts' expectations of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business's revenue for the quarter was up 102.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($3.36) earnings per share. BioNTech has set its FY 2025 guidance at EPS. Research analysts forecast that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts have commented on the company. The Goldman Sachs Group assumed coverage on BioNTech in a research report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price objective on the stock. Morgan Stanley upped their price objective on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, July 10th. JPMorgan Chase & Co. lowered their price objective on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Leerink Partners set a $112.00 price objective on BioNTech in a research report on Monday, June 2nd. Finally, Wells Fargo & Company set a $150.00 target price on BioNTech and gave the company an "overweight" rating in a research report on Tuesday, August 5th. Thirteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $135.80.
Read Our Latest Research Report on BNTX
BioNTech Profile
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Further Reading
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
